More on Efforts to Reform Pay-for-Delay Drug Settlements

by Brian Wolfman

Last month, I blogged here about FTC Chair Jon Leibowitz's call to eliminate or narrow "pay-for-delay" drug settlements. In pay-for-delay settlements, a brand-name drug company pays a generic company that has challenged the brand-name company's patent to stay out of the market. Today, in this editorial, the Washington Post endorses legislation to ban most of these settlements.